Treatment of Acute Promyelocytic Leukemia with WBC Above 10,000/ml (High-Risk APL)
Acute promyelocytic leukemia presenting with a white blood cell count above 10,000/ml defines the high-risk category. This threshold directly shapes the treatment strategy and is the basis for risk-stratified decision-making in APL.
APL is stratified by presenting WBC count. A WBC above 10,000/ml places patients in the high-risk group — a distinction most clinicians now use as the primary boundary between high risk and low/intermediate risk (≤10,000/ml). This classification is the defining feature of this protocol's target population.
The approach for this high-risk subset — including relapsed and refractory disease — centres on combination salvage strategies. Arsenic-based agents, used alone or combined with other agents, form a cornerstone of the regimens evaluated in this setting. The complete algorithm, specific combinations, and all dosing details are available in the full protocol.
References
- In the era of ATRA, APL has been stratified into three categories of risk with regards to relapse-free survival (RFS): WBC >10,000/ml (high-risk), WBC ≤10,000 ml with platelet count ≤40,000/ml (intermediate-risk), and WBC ≤10,000/ml with platelet count >40,000/ml (low-risk).
- Today, most clinicians will categorize APL within two categories, high risk (>10,000/ml) and low/intermediate risk.
- The activity of ATO in relapsed disease has been demonstrated in multiple studies.
- The combination of ATO and other agents such as idarubicin and GO have also shown efficacy in regaining molecular CR.
View source ↗